Unlocking significant potential
NeRRe’s ambition is to unlock the significant potential of its unique neurokinin-1 receptor antagonist (NK-1RA) pipeline, and in particular to progress orvepitant to full Phase 3 readiness in Refractory or Unexplained Chronic Cough (RUCC).
NeRRe’s ambition is to unlock the significant potential of its unique neurokinin-1 receptor antagonist (NK-1RA) pipeline, and in particular to progress orvepitant to full Phase 3 readiness in the lead indication of Refractory or Unexplained Chronic Cough (RUCC) by 2020. The company intends to discuss the positive Phase 2b results and the proposed Phase 3 pivotal programme for orvepitant in RUCC with regulators in Q4 2019.
The depth of the pipeline also allows for other neural hypersensitivity conditions including additional cough indications to be explored.
The company’s two earlier stage selective NK-1RA development compounds are NT-949 which is Phase 1 ready and NT-432 which is at the candidate selection stage ready to enter pre-clinical development.
The selective NK-1RAs in NeRRe’s portfolio have the potential to treat a range of chronic conditions caused by neural hypersensitivity associated with NK-1R system dysfunction, such as RUCC. There is a strong biological rationale, including pre-clinical models of the disease and human experimental medicine data, underlying the importance of the NK-1 receptor and its primary endogenous ligand, Substance P (SP), as mediators of RUCC. The potential for orvepitant to return to normal functioning the hypersensitive neural networks is clear.
Orvepitant has been administered to approximately 900 individuals to date and has demonstrated a clear benefit and reduces the symptoms of RUCC in the open label Phase 2a study “VOLCANO-1” and this benefit was confirmed more recently in the dose range finding Phase 2b study “VOLCANO-2”. Orvepitant is now being advanced by NeRRe into a Phase 3 program.
If you are interested in talking to us about partnering any of our pipeline assets, please contact us via email at: firstname.lastname@example.org.